Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215066 | 1.00 | KMT2A (0.44) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL22938025 | 0.85 | SMN1; SMN2 (0.44) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL18982762 | 0.83 | KMT2A (0.45) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL826639 | 0.83 | KMT2A (0.45) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL15123482 | 0.83 | KMT2A (0.45) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL27588944 | 0.81 | RXRA (0.50) | KMT2AHDAC3HDAC4HDAC2HDAC8 | |
| SCHEMBL13114549 | 0.81 | KCNN4 (0.44) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL20659354 | 0.81 | KCNN4 (0.44) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL31612945 | 0.81 | KCNN4 (0.44) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL2171798 | 0.80 | CYP1A2 (0.59) | KMT2AMEN1SMN1; SMN2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| EP-1907381-A4 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| EP-1907381-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20070173434-A1 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| EP-1709014-B1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007008501-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1709014-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070905-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | KMT2A 1608/4885MEN1 4802/4885SMN1; SMN2 4641/4885 |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | KMT2A 1204/4885MEN1 4812/4885SMN1; SMN2 4695/4885 |
| US-20070173434-A1 | Antidiabetic oxazolidinediones and thiazolidinediones | PPARD, PPARA, PPARG | KMT2A 1480/4885MEN1 4762/4885SMN1; SMN2 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.